Day Pitney Grows National IP Practice With Boston Life Sciences Patent Team

Day Pitney LLP is pleased to announce that Dr. Christopher Cowles and Dr. Richard Emmons have joined the firm's Boston office as Partners in its Intellectual Property (IP) and Technology practice group. Their arrival bolsters the firm's existing IP capabilities by bringing additional experience in patent prosecution and counselling and expanding the firm's ability to serve a diverse array of technology sectors. Dr. Cowles and Dr. Emmons hold Ph.D.s in biomedical sciences and developmental biology, respectively, and are eager to address the growing demand for intellectual property services in Boston's thriving biotechnology market. They are joined by Dr. Erica Fishel, an associate with a Ph.D. in molecular biology.

"Adding Chris and Richard is a game-changer for our patent practice. They bring exceptional life sciences and biotech patent experience, coupled with a proven record of supporting corporate deal flow and transactional success. They will immediately enhance our ability to serve clients and their evolving needs in these critical areas," remarked Carrie Webb Olson, chair of Day Pitney's IP and Technology practice.

At Day Pitney, Drs. Cowles and Emmons will focus on continuing to grow a high-value life sciences-focused IP practice dedicated to protecting branded biotechnology and pharmaceutical inventions, supporting corporate transactions, and helping technology investors create value. Their work will span all aspects of biotechnology and life sciences development, including developing, protecting, funding, and monetizing technologies in the cell-, gene-, nucleic acid-, and immuno-therapy sectors. 

With over 20 years of legal experience, Dr. Cowles routinely counsels biotechnology companies and academic clients in the nucleic acid therapeutics, immunotherapy, genomics, and personalized medicine sectors in patent preparation, prosecution, IP due diligence, portfolio management, and freedom-to-operate analyses. Dr. Emmons, with nearly 20 years of legal experience, counsels clients on global patent strategy, IP portfolio creation and management, patent application preparation and prosecution, freedom-to-operate analysis, opinion work, inter partes and post-grant review (IPR/PGR), and complex landscape searches, drawing on nearly two decades of research experience in developmental biology, genetics, and epigenetics. Dr. Emmons leads due diligence for private and public companies, family offices, and investors, including private equity firms and hedge funds. 

"Joining Day Pitney is the right move for us – and even more importantly for our clients – at the right time," commented Dr. Cowles. "We were drawn to Day Pitney's growing IP team, and the firm's long-standing corporate life sciences and biotech practice. Our combined experience in patent prosecution, IP strategy, and transactional work, coupled with Day Pitney's platform and client base, creates an exceptional opportunity to serve the evolving needs of innovators in these dynamic fields," added Dr. Emmons. 

Drs. Cowles and Emmons bring diverse and comprehensive academic backgrounds to their roles. Dr. Cowles earned his Ph.D. from the University of California, San Diego, completed a Damon Runyon postdoctoral fellowship in genomics at the Whitehead Institute at MIT, earned a J.D., cum laude, from Suffolk University Law School, and obtained a B.A., magna cum laude, from Rice University. Dr. Emmons earned his Ph.D. from Washington University School of Medicine, completed Kirschstein NRSA postdoctoral research in epigenetics at Harvard Medical School, earned a J.D. from Suffolk University Law School, and received a B.A. in Ecology from the College of the Atlantic. They are both admitted to practice in Massachusetts.

No aspect of this advertisement has been approved by the highest court of any state. Prior results do not guarantee a similar outcome.